Funder
Beijing Natural Science Foundation
Reference48 articles.
1. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial;Baas;Lancet,2021
2. Systemic therapy for pre-treated malignant mesothelioma: a systematic review, meta-analysis and network meta-analysis of randomised controlled trials;Banna;Eur. J. Cancer,2022
3. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment;Bibby;Eur. Respir. Rev. Off. J. Eur. Respir. Soc.,2016
4. Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma;Billé;J. Thorac. Oncol.,2016
5. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications;Blum;Nat. Commun.,2019